Meller MM,Toossi N,Johanson NA,Gonzalez MH,Son M-S .2016 .Risk and cost of 90-day complications in morbidlyand superobese patients after total knee arthroplasty. J Arthroplasty, 31(10) : 2091-98.
Judge A,Cooper C,Williams S,Dreinhoefer K .2010 .Patient reported outcomes one year after primary hipreplacement in a European Collaborative Cohort. ArthritisCare Res, 62 : 480-8.
Chan YK,Chiu KY,Cheng SW,Ho P. .2004 .The incidence of deepvein thrombosis in elderly Chinese suffering hip fractures islow without prohlyaxis: a prospective study using serialduplex Ultrasound. J Orthop Surg, 12 : 178-83.
Aziz I. .2005 .Frequency of deep vein thrombosis in high risksurgical patients. J Coll Physicians Surg Pak, 15 : 299-01.
Kucher N. .2011 .Clinical practice. Deep-vein thrombosis of theupper extremities. N Engl J Med, 364 : 861-69.
Cohen AT,Asia-Pacific Thrombosis Advisory Board. AsiaPacific Thrombosis Advisory AT .2010 .Board consensus paper onprevention of venous thromboembolism after majororthopaedic surgery. Thromb Haemost, 104 : 919-30.
Piovella F,Wang CJ,Lu H,Lee K,Lee LH,Lee WC .2005 .Deep-vein thrombosis rates after major orthopedic surgeryin Asia: an epidemiological study based on postoperativescreening with centrally adjudicated bilateral venography. J Thromb Haemost, 3 : 2664-70.
Warwick D .2012 .Prevention of venous thromboembolism in totalknee and hip replacement. Circulation, 125 : 2151-55.
Ahmad T,Zaman AU,Ahmad I,Akram R,Aziz A . .Frequency and risk factors for deep vein thrombosis afterorthopaedic surgery. Pak J Med Health Sci2016;, 10(3) : 744-49.
Papadopoulos DV,Kostas‐Agnantis I,Gkiatas I,Ziara P,Korompilias AV .2017 .The role of new oralanticoagulants in orthopaedics: an update of recent evidence. Eur J Orthop Surg Traumatol, 27 : 573-82.
Feng W,Wu K .2015 .Oral direct factor Xa inhibitor versusenoxaparin for thromboprophylaxis after hip or kneearthroplasty: systemic review, traditional meta‐analysis,dose‐response meta‐analysis and network meta‐analysis. Thromb Res, 136 : 1133-44.
Ye Jiajing CZ,Haizhao W,Lingjun J,Zhong Z,Tsunami C,Zhenghua H C .2017 .Safety of rivaroxaban combined with aspirinafter total hip and knee arthroplasty and its effectivenessin prevention of cerebral infarction. Chin J Bone JointInjury, 32 : 1053-55.
Tang Y,Wang K,Shi Z,Yang P,Dang X. .2017 .A RCT study of Rivaroxaban, low‐molecular‐weight heparin, and sequential Medication regimens for the prevention of venous Thrombosis after internal fixation of hip fracture. Biomed Pharmacother, 92 : 982-88.
Anderson DR,Dunbar MJ,Bohm ER .2013 .Aspirin versus low‐Molecular‐weight heparin for extended venous Thromboembolism prophylaxis after total hip arthroplasty: A randomized trial. Ann Intern Med, 158 : 800-06.
Huang Q,Xing SX,Zeng Y,Si HB,Zhou ZK,Shen B . .Comparison of the efficacy and safety of aspirin and Rivaroxaban following enoxaparin treatment for prevention of venous thromboembolism after hip fracture surgery. Orthop Surg, 11(5) : 88694.
Piovella F,Wang CJ,Lu H .2005 .vein thrombosis rates After major orthopedic surgery in Asia. An epidemiological Study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost, 3 : 2664-2670.
Yu HT,Dylan ML,Lin J,Dubois RW .2007 .Hospitals' compliance With prophylaxis guidelines for venous Thromboembolism. Am J Health Syst Pharm, 64 : 69.
Eichinger S,Kyrle PA .2004 .Prevention of deep vein thrombosis in orthopedic surgery. Eur J Med Res, 9 : 112-118.
Association CO,Quinlan DJ,Eikelboom JW,Dahl OE,Eriksson BI,Sidhu PS .2007 .Association between asymptomatic deep veins thrombosis detected by venography and symptomatic Venous thromboembolism in patients undergoing elective Hip or knee surgery. J Thromb Haemost, 5 : 1438-1443.